[Pd(η3-C3H5)(μ-Cl)]2 + 4PPh3 and [(η3-C3H5)PdCl(PPh3)] + 1PPh3 do not produce the cationic (π-allyl)palladium(II) complex [(η3-C3H5)Pd(PPh3)2]+Cl− but a neutral (σ-allyl)palladium(II) chloride complex [(η1-CH2=CH−CH2)PdCl(PPh3)2] in DMF and THF. This latter complex is also formed when one equivalent of chloride ion is added to [(η3-C3H5)Pd(PPh3)2]+(BF4)−, leading to the conclusion that [Pd(η3-C3H5)(μ-Cl)]2 + 4PPh3 and [(η3-C3H5)Pd(PPh3)2]+ (BF4)− are not equivalent precursors for the palladium-catalyzed allylic substitutions when they are performed in the absence of added chloride ions. The (σ-allyl)palladium(II) chloride complex [(η1-CH2=CH−CH2)PdCl(PPh3)2] is also formed instead of [(η3-C3H5)Pd(PPh3)2]+(AcO)− when the oxidative addition of allylic acetate to palladium(0) complexes, such as [Pd0(dba)2] + 2PPh3, is performed in the presence of chloride anions. A cationic (π-allyl)palladium(II) complex is thus not formed in the presence of chloride ions, which are either delivered by the catalytic precursor or deliberately added.
No takes yet. Share an insight, caveat, or question.
Amatore et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: